Form 4: enGene Holdings Inc. Executive Receives Stock Option Grant

Joan Connolly, Chief Technology Officer of enGene Holdings Inc., was granted a non-qualified stock option for 210,000 shares on October 21, 2024.

Summary

• Joan Connolly, the Chief Technology Officer of enGene Holdings Inc., received a stock option grant.
• The grant, awarded on October 21, 2024, is for 210,000 shares of enGene Holdings Inc. common stock.
• The exercise price of the stock option is $9.83 per share.
• The option vests at 25% on October 21, 2025, and the remaining portion vests monthly over the following three years, contingent upon Ms. Connolly's continued service.
• The stock option expires on October 21, 2034.
• The grant was made as an inducement award outside of the Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan, in accordance with NASDAQ Listing Rule 5635(c)(4).

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects a standard executive compensation practice, indicating confidence in the company's future and the executive's role in it.

Positives

• The stock option grant serves as an incentive for the Chief Technology Officer to remain with the company.
• The vesting schedule aligns the executive's interests with the long-term performance of the company.
• The grant was made in compliance with NASDAQ regulations.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain key personnel, aligning their interests with the company's long-term success. This grant is consistent with industry standards for executive compensation.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Biogen routinely use stock options to incentivize their key employees.
• The vesting schedule and exercise price are typical for similar grants in comparable companies.

Stakeholder Impact

• The stock option grant incentivizes the Chief Technology Officer, potentially benefiting shareholders through innovation and company growth.
• Employees may view this as a positive sign of investment in leadership.

Key Dates